As semaglutide treatments become common, patients report thinning legs and hollowed faces; learn why these changes happen and evidence-based ways to minimise them
The emergence of visible body changes during semaglutide treatment has become a frequent topic among patients and clinicians. Social media users coined terms such as Ozempic legs and Ozempic face to describe noticeable thinning of the limbs and hollowing of the cheeks after significant weight loss.
While these phrases are informal, they capture real concerns: experts warn that rapid, drug-supported weight loss can reduce both fat and lean mass, sometimes producing an aged or wasted appearance if left unaddressed.
It is important to understand that the cosmetic changes people describe are linked to the pattern and speed of weight loss rather than a unique toxic effect of the medicine.
Both Ozempic and Wegovy contain the active ingredient semaglutide, a GLP-1 receptor agonist that lowers appetite and energy intake. Differences in licence and dose mean Wegovy (commonly used at 2.4 mg weekly for weight management) typically produces larger weight reductions than Ozempic (licensed for type 2 diabetes at 0.5 mg, 1 mg or 2 mg weekly in the UK), and the greater or faster the weight loss the more apparent body-composition changes can be.
How semaglutide changes body composition
Weight loss involves more than shedding adipose tissue. When calorie intake falls significantly, the body draws on multiple fuel sources: subcutaneous fat, visceral fat and, unless protected, some skeletal muscle. Clinical studies using DEXA scans in semaglutide trials show that a portion of total weight loss can be lean mass, though the proportion varies between individuals and depends on diet, activity and baseline composition. Even when absolute muscle mass declines, relative lean mass as a percentage of body weight can rise because fat loss is often larger, but the visible effect in the limbs and face is what concerns many patients.
Why limbs and face change more for some people
Fat distribution and skin quality are largely determined by genetics, age and sex. The limbs and face sometimes lose fat earlier or more noticeably than the trunk; older adults with reduced skin elasticity will show more loose or crepey tissue after volume loss. Loss of underlying muscle amplifies this effect: a thigh that loses subcutaneous fat and some muscle can appear deflated, with tendons and bony landmarks more visible. These outcomes are not unique to semaglutide—any rapid, sustained weight loss can produce similar changes.
Symptoms to monitor and when to seek help
Some people report leg aches, cramps or weakness during significant weight loss. These symptoms usually stem from reduced caloric or protein intake, dehydration, or deconditioning rather than a direct pharmacological toxicity. However, there are clear red flags that require urgent assessment: severe abdominal pain radiating to the back (possible pancreatitis), persistent jaundice or severe upper abdominal pain (possible gallbladder disease), sudden severe leg pain with swelling or redness (possible DVT), and sudden breathlessness or chest pain (possible PE). Patients with type 2 diabetes who are also on insulin or sulfonylureas should watch for hypoglycaemia and consult their clinician about medication adjustments.
Reporting and continuing treatment
Anyone experiencing worrying symptoms should contact their GP or diabetes specialist promptly and avoid stopping treatment without medical advice. Suspected adverse effects in the UK can be reported to the MHRA via the Yellow Card scheme. Clinicians will review the treatment plan, consider nutritional and exercise support referrals, and decide whether dose changes or alternative strategies are appropriate.
Practical steps to reduce muscle loss and manage skin changes
Several evidence-based measures reduce the risk of unwanted muscle and skin changes during weight loss. Prioritise adequate protein intake: the UK Reference Nutrient Intake is 0.75 g/kg/day for adults, but higher intakes are commonly advised during weight loss to preserve lean mass. Combine diet with regular resistance exercise—weight training, bodyweight routines or resistance bands stimulate muscle synthesis and are recommended at least twice weekly. Gradual weight loss where clinically safe, good hydration and realistic expectations about skin elasticity also help.
For persistent skin laxity, topical moisturisers may modestly improve texture, but surgical options such as body-contouring procedures are typically available only for functional problems on public health systems; cosmetic-only cases often turn to private care. A GP or specialist can refer patients to a dietitian, physiotherapist or surgeon to discuss personalised plans. Remember that both benefits and cosmetic trade-offs are part of the broader clinical picture when using semaglutide therapies.
In summary, the so-called Ozempic legs and Ozempic face reflect real, treatable consequences of rapid weight loss: combination approaches—nutrition, strength training and clinical supervision—are the best way to preserve muscle and support skin health while benefiting from the metabolic advantages of GLP-1 therapies.
